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Abstract
Background: Inhalation devices represent per sé critical factors because they can affect the therapeutic outcomes
independently of the drug used. The role of patients’ usability and preference (PUP) for Dry Powder Inhalers (DPIs)
is high indeed because they can influence the extent of the adherence to treatment and the therapeutic outcomes.
Aim of the study was to assess and compare the PUP of three different DPIs in out-patients with persistent airflow
limitation due to asthma or COPD.
Methods: The PUP of three different DPIs (Breezhaler; Genuair; Handihaler) were investigated by means of the
Handling Questionnaire in out-patients with persistent airflow limitation needing an inhalation therapy. Patients had
to report their preference before and after the nurse’s instruction on the handling of each device. The nurse had
also to note the critical steps during the patient’s procedure for actuation; to count the number of attempts
needed for actuating the device properly, and to measure the time (in sec.) required for these procedures. Data
were collected up to three attempts per device.
Statistics: Welch test was used for normal distributed variables, while the Wilcoxon test for not normal distributed
variables. The χ2 test and the ANOVA test were also used. Univariate and multivariate regressions were also
performed in order to investigate the effect of patients’ characteristics and of technical differences of each device
on their proper use.
Results: Three hundred thirty-three consecutive out-patients (age range 55–58 years, and well matched for gender),
with persistent airway limitation of different severity were investigated, suffering from bronchial asthma (n = 175) or
from chronic obstructive pulmonary disease (COPD) (n = 158). In particular, 127 patients (38 %) tested the three DPIs,
while 110 (33 %) tested Breezhaler and Genuair, and 96 (29 %) Breezhaler and Handihaler. More than 50 % of patients
who tested all devices preferred the Genuair and perceived this device as the easiest to use. The nurse’s judgement
confirmed their opinion. When compared to the other two DPIs, Genuair proved the least problematic either
according to the patients’ judgement and to the nurse’s opinion. Mean number of attempts aimed to achieving the
first proper actuation was lower with Genuair than with Breezhaler and Handihaler (1.5 vs 2.5–2.6, p < 0.0001). Finally,
Genuair also proved the easiest to use and the least problematic according to the nurse judgement (0.0001), the most
easily learned (0.0001), and that one with a successful rate of more than 56 % at the first attempt. Breezhaler and
Handihaler needed an average of about one additional attempt to be used properly (p < 0.0001), and their usability
proved significantly more difficult (OR of successful rate between 0.15 and 0.17, p < 0.001). In general, older patients
needed more attempts to perform their first proper inhalation; their successful rate was lower, and they needed more
time to learn how to use devices properly: with Genuair these differences were minimized.
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Conclusions: The possibility of grading objectively the performance of different DPIs in terms of their usability and
therapeutic convenience in daily life represents a crucial operational opportunity to pursue. To note that a substantial
discrepancy exists between the patients’ belief “at glance” and the patients’ effective usability with can be registered
with some devices. From a general point of view, devices requiring less manual actions for their actuation confirmed
their better usability and proper handling after less attempts. In particular, Genuair came out as the most preferred DPI
also when several different aspects of preference and usability are assessed objectively and compared.
Keywords: Breezhaler, Bronchial Asthma, COPD, Genuair, Handihaler, Handling Questionnaire, Patients' preference,
Patients' usability
Background
Respiratory drugs are preferably delivered via the inhalation
route both in bronchial asthma or in chronic obstructive
pulmonary disease (COPD) because they target directly the
lungs; offer a more rapid onset of action; allow the use of
smaller doses, and consent a better efficacy-to-safety ratio
compared to systemic treatments [1–4].
The inhalation devices represent per sé critical factors
because they are able to affect the therapeutic outcomes
substantially and independently of the drug used. Actu-
ally, several aspects specifically related to the devices can
contribute to the effectiveness of treatment, such as their
capability to consent the inhalation of a sufficient respi-
rable fraction of the drug (with a particle size ≤ 6 μ); the
dose reproducibility; the dose precision and stability, and
the comfortable usability in daily life use, particularly in
elder patients [5–8].
The development of the Dry Powder Inhalers (DPIs)
represented a substantial forward step in the evolution of
the inhalation strategy: they do not contain propellants;
they optimize the consistency of inhaled drug and the
extent of its lung deposition, and generally minimize the
role of patient’s cooperation and comprehension in limi-
ting the effectiveness of inhalation [9, 10].
The patients’ usability and preference (PUP) for inhaled
devices in general, and for DPIs in particular, still represent
two relevant issues to assess as their role still is high indeed
and can influence the extent of the patient’s adherence to
inhalation treatment and, consequently, the therapeutic
outcomes [1, 11–13].
The PUP level is usually assessed by means of validated
tools (such as, questionnaires) [14, 15]. The Handling Ques-
tionnaire is a validated questionnaire which was specifically
designed to identify and compare the determinants of
choice and acceptability of different inhalation devices in
patients with persistent airflow limitation, namely bronchial
asthma and chronic obstructive pulmonary disease (COPD)
[14, 15].
Aim of the study was to assess by means of the Handling
Questionnaire and compare the PUP of three different DPIs
in out-patients with persistent airflow limitation due to
asthma or COPD, according to a controlled design where
the patient’s opinion had to be compared to the objective
judgment of a supervising expert nurse.
Methods
In order to investigate the patients’ PUP of different DPIs,
the Handling Questionnaire was administered (from Sep-
tember to December 2015) to consecutive patients, with
persistent airway obstruction needing an inhalation ther-
apy. The Handling Questionnaire is anonymous; it allows
the assessment of different domains of PUP, and takes also
into account the patients’ age and gender, together with
their previous experience with and their previous educa-
tional approach to inhalation devices. Patients with and
without previous experience and/or instruction to inhal-
ation devices were included in order to investigate the
duration of their instruction.
PUP was measured for three different DPIs: the
Breezhaler, the Genuair, and the Handihaler. These devices
were chosen because they need a different number of
actions for their actuation (such as: 7; 3, and 8, respec-
tively), and are also differently characterized in terms of
their intrinsic resistance (such as: very low (0.017 kPa0.5 L/
min); medium (0.031 kPa0.5 L/min), and high (0.058 kPa0.5
L/min, respectively).
The study plan consisted of three steps. In the first step,
the functioning of each device was shown to each patient
in random order by a professional nurse, highly expert in
educational programs and specifically trained in the tech-
nical and the psychological aspects of the study. Patients
were then required to report their preference simply on
the basis of their opinion “at glance”, together to the
reason of their preference. In the following phase of the
study (that is, after the nurse had instructed each patient
on the functioning of each device), each patient had to
prepare the actuation from each device by him/herself,
while the nurse was monitoring his/her technicality. The
nurse had also to note the critical issues; to count the
number of attempts needed for actuating the device pro-
perly, and to measure the time (in sec.) required for these
procedures. During this step of the study (that is once
experienced the device directly), each subject was required
to report once again his/her preference and to specify the
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reason, but on the basis of a personal, practical experience.
At the end of this step, the nurse added her comments to
those of each patient, in order to compare the two opinions
at the end of the study. In the final step, patients were
required to give for the third time their preference, con-
cerning different aspects of acceptance and usability of each
device.
As the three devices to compare were different in terms
of procedures and number of actions for their actuation,
the time spent in explaining the correct functioning of
each device and in instructing each patient to the use of
each device was measured (in sec.) and compared,
together with the time required to each patient for actua-
ting each device effectively. Data were collected up to
three attempts per device.
Statistics
Descriptive statistics are presented as mean ± standard de-
viation (SD), or simple percentage, as appropriate. Possible
differences among devices were analyzed using the Welch
test, the Wilcoxon test or the ANOVA test as appropriate.
The χ2 test was used for categorical variables. A p <0.05
was accepted as the level of statistical significance for all
tests. All analyses were performed using computer soft-
ware R 3.1.2 [16]. Univariate and multivariate regression
were also performed in order to investigate the effect of
patients’ characteristics and of technical differences of
each device on their proper use. Factors associated with
the proper use of DPIs were analyzed using univariate and
multivariate linear regressions. Variables with p less than
0.1 in the univariate analysis were included in the multi-
variate model from which we extracted only statistically
significant values (p < 0.05) by using the stepwise selection
technique (backward).
Results
The overall patients’ sample consisted of 333 consecutive
out-patients with persistent airflow limitation of different
severity, either due to bronchial asthma (n = 175), or to
chronic obstructive pulmonary disease (COPD) (n = 158).
In particular, 127 patients (38 %) tested all the three DPIs,
while 110 (33 %) tested Breezhaler and Genuair, and 96
(29 %) Breezhaler and Handihaler.
The characteristics of the patients’ sample and data of
patients’ usability for each device are reported in Table 1,
together with the mean duration of the three nurse’s
educational explanations and of the corresponding num-
ber of patients’ operational attempts. To note that all the
patients recruited had the opportunity to use all these
DPIs in their past, but also other DPIs (namely, the
Diskus and the Turbohaler), at a variable regimen and
duration, resulting the corresponding distribution ran-
domly comparable within the three sub-groups tested in
the present study.
At baseline, patients in the three device sub-groups were
well matched in terms of mean age (ranging 55–58 years);
gender; original cause for their airway obstruction; pre-
vious experience with and instruction to DPIs (all p = ns)
(Table 1). More than 50 % of patients who tested all
devices preferred the Genuair and perceived this device as
the easiest to use, the nurse’s judgement confirming their
opinion (Fig. 1, where the comparison among Breezhaler,
Genuair, and Handihaler is reported). The remaining pa-
tients appear hesitant in judging devices and less than 5 %
chose Breezhaler or Handihaler. When only Breezhaler
and Genuair were tested, the result was similar (Fig. 1, see
comparison Breezhaler vs Genuair), while, if Genuair was
not included in the comparison (Fig. 1, see comparison
Breezhaler vs Handihaler), about 80 % preferred to not
choose any device.
Genuair was the most preferred in terms of appearance,
comfort, safety and convenience (Fig. 2); about 90 % of
patients chose Genuair on the basis of the series of prefe-
rence questions “Which device offers the most conve-
nience in terms of…?” followed by Handihaler (8 %) and
Breezhaler (2 %) (Fig. 2).
When compared to the other two DPIs, Genuair proved
the least problematic either according to the patients’
judgement and to the nurse’s opinion (Fig. 3). In general,
patients seemed to underestimate the difficulties encoun-
tered when practicing the Breezhaler: actually, approxi-
mately 50 % of patients who tested Breezhaler found some
substantial difficulties (both considering all patients and
the subgroup analysis), while this proportion increased up
to 90 % according to the nurse’s judgement (Fig. 3). There
was a perfect agreement between patients and nurse in
judging the use of Handihaler as quite difficult.
The number of attempts required to patients for prepa-
ring the first proper inhalation represents a very important
indicator of efficiency and practicality of the devices inves-
tigated in the present study. Mean number of attempts
before achieving the first proper actuation was lower with
Genuair than with Breezhaler and Handihaler (1.5 vs 2.5–
2.6, p < 0.0001). Furthermore, 56 % of patients learned
how to use Genuair properly after the first demonstration,
while more than 80 % of patients were unable to use the
other two devices properly after the first demonstration
(Table 1). The time for the nurse’s explanation and that
needed to patients for preparing the inhalation with
Genuair and Handihaler proved similar. Nevertheless, the
total time spent in learning how to use the former device
properly was significantly lower than that of the latter
device (p < 0.0001). The corresponding total time for
Breezhaler was the highest (more than 10 min), due to the
highest number of manoeuvres required, as well as to the
longest explanation (Table 1).
Univariate and multivariate analyses showed that some
significant differences in device usability were mainly due
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to patients’ age and to devices themselves (Table 2). Older
patients needed more attempts to perform the first proper
inhalation (0.07 every 5-years increment, p < 0.0001).
Moreover, their successful rate was lower (OR = 0.84, p <
0.0001) and they needed more time to learn how to use
devices properly (an average of 0.25 min, p < 0.0001).
Breezhaler and Handihaler needed an average of about
one additional attempt to be used properly (p < 0.0001),
and their usability proved significantly more difficult (OR
of successful rate between 0.15 and 0.17, p < 0.001). On
the contrary, a previous experience in the use of DPIs did
not seem to facilitate their proper use (OR = 0.64, p <
0.0001). The overall comparison among the three devices
is reported in Fig. 4: Genuair resulted the easiest to use
and the fastest to learn, while no significant difference was
detected between Breezhaler and Handihaler either in the
number of attempts needed to actuate the first proper
inhalation or in the successful rate at the first attempt. In
Table 1 Characteristics of tested devices, baseline characteristics of patients, and differences in usability
Breezhaler Genuair Handihaler p
Device characteristics
Manoeuvres (n)a 7 3 4
Time spent by nurse with
patients during trainingb (min)
1st attempt 2.8 ± 0.1 1.3 ± 0.1 1.4 ± 0.1 p < 0.0001
2nd attempt 4.2 ± 0.2 1.8 ± 0.1 2 ± 0.2 p < 0.0001
3rd attempt 5.0 ± 0.3 2.1 ± 0.2 2.7 ± 0.2 p < 0.0001
Patient characteristics
Patients (N) 333 237 223
Age (years) 55.2 ± 18.3 54.8 ± 17.5 57.8 ± 17.9 NS
Sex (% male) 46.5 % 49.4 % 43.9 % NS
Disease (% COPD) 47.4 % 47.7 % 51.6 % NS
Previous experience with DPI 63.7 % 66.7 % 64.6 % NS
Previous instruction to use of DPI 60.7 % 64.1 % 62.8 % NS
Usability
N. attempts before achieving the first proper inhalation 2.6 ± 1.1 1.6 ± 0.8 2.5 ± 1.1 p < 0.0001
Successful rate at the first attempt (%) 18.0 % 55.7 % 19.3 % p < 0.0001
Total time required for the first proper inhalationb (min) 10.3 ± 5.0 2.5 ± 1.6 4.9 ± 2.7 p < 0.0001
DPI dry powder inhaler
aNumber of operations to prepare the inhalation
bIncluding patient time and nurse demonstration
Fig. 1 Patient/nurse opinion and preferences. *patient judgement (after the nurse instruction), ** nurse report. BGH: patients tested all devices,
BG: patients comparing Breezhaler with Genuair, BH: BG: patients comparing Breezhaler with Handihaler
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particular, as Breezhaler required the longest to explain
and to use, the total time needed for the first proper inhal-
ation resulted significantly lower with Handihaler than
with Breezhaler (p < 0.0001).
Subgroup analysis: asthma vs COPD patients
Patients with asthma were significantly younger than
COPD patients (44 ± 16 vs 68 ± 11, p < 0.0001) and less
trained in the use of DPIs: less previous experienced (56
vs 72 %, p < 0.005), and less instructed in their use (55 vs
67 %, p < 0.05). No differences were be observed by sex
(Table 2).
Despite the difference in asthma and COPD patients,
in both groups the Genuair resulted the most preferred
and teh Handihaler the most dificult to use.
In general terms, asthma patients had less difficulties
in learning how to use the devices properly: the mean
number of attempts was lower in asthma than in the
COPD group (2.1 ± 1.1 vs 2.5 ± 1.1, p < 0.0001). Corres-
pondingly, the successful rate at the first attempt was
also higher (38 vs 21 %, p < 0.0001).
According to these results, the time spent by each
patient to learn how to use devices properly was lower in
the asthma group by an average of more than 1 min
(5.9 ± 4.8 vs 7.0 ± 5.1 min, p < 0.001).
Discussion
Even if respiratory drugs should be preferably deliv-
ered via the inhalation route, the choice of the inhaler
device to prescribe frequently is empirically guided in
Fig. 2 Response to the question “Which device offers the most convenience in terms of…?”: the patients’ opinion
Fig. 3 Presence of any problems found after the use of devices: the patients’ vs the nurse’s judgement. BGH: patients tested all devices, BG:
patients comparing Breezhaler with Genuair, BH: BG: patients comparing Breezhaler with Handihaler
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real life, and the determinant of choice are usually
completely independent of the knowledge of the
technological characteristics of devices and of their
performance [17–20].
It is well known since long ago that specific education is
essential in order to maintain and improve the patients'
usability of prescribed device(s), even if it represents a
relevant issue in usual daily activity because it is time
consuming [21], and specific professional figures are
frequently missing. Furthermore, it should be considered
that also health care professionals (such as: GPs, medical
students, respiratory physiotherapists, pharmacists, and
even nurses and lung physicians) frequently prove an
inadequate skill in using inhalation devices [13], and then
they cannot support their patients who are prescribed
these devices for any aid.
The determinants of patients’ choice and preference rep-
resent a crucial issue which can affect the outcomes of the
therapeutic strategy, particularly if the device requires a
complicated sequence of manoeuvres for its proper actu-
ation, and the procedures are not preceded or associated
to a sufficient patient’s instruction [4, 22].
As patients with persistent airflow limitation, either
asthma or COPD patients, usually need long-term inha-
lation treatments and should then be familial with their
device(s) for long periods, their PUP represent a crucial
point indeed in terms of their therapeutic strategy. Unfor-
tunately, the patient’s opinion was only episodically
regarded as a crucial variable which can influence the
effectiveness of their treatment, even substantially [17–20].
This aspect is of greater value when considering that, at
present, the majority of molecules available on the market
Table 2 Predictors of proper inhalation achieving: results of univariate and multivariate linear regressions on patients characteristics
and tested devices
Attempts before achieving the first proper
inhalation (N)
Univariate analysis Multivariate analysis
delta (95 % C.I.) p delta (95 % C.I.) p
Age a 0.08 (0.05─0.10) < 0.0001 0.07 (0.05─0.09) < 0.0001
Sex (female) −0.03 (-0.18─0.12) NS
Disease (COPD vs asthma) 0.36 (0.21─0.51) < 0.0001
Previous experience with DPI 0.14 (-0.02─0.30) NS
Previous instructed to DPI 0.12 (-0.04─0.28) NS
Device (Breezhaler vs Genuair) 1.01 (0.84─1.18) < 0.0001 1.00 (0.84─1.16) < 0.0001
Device (Handihaler vs Genuair) 0.91 (0.73─1.10) < 0.0001 0.87 (0.69─1.05) < 0.0001
Successful rate at the first attempt (%) Univariate analysis Multivariate analysis
OR (95 % C.I.) p OR (95 % C.I.) p
Age a 0.85 (0.81─0.89) < 0.0001 0.84 (0.80─0.88) < 0.0001
Sex (female) 0.96 (0.71─1.3) NS
Disease (COPD vs asthma) 0.43 (0.31─0.58) <0.0001
Previous experience with DPI 0.59 (0.43─0.81) < 0.001 0.64 (0.45─0.92) < 0.05
Previous instructed to DPI 0.64 (0.47─0.88) < 0.01
Device (Breezhaler vs Genuair) 0.17 (0.12─0.25) < 0.0001 0.15 (0.10─0.22) < 0.0001
Device (Handihaler vs Genuair) 0.19 (0.12─0.29) < 0.0001 0.17 (0.11─0.27) < 0.0001
Total time required for the first proper inhalationb (min) Univariate analysis Multivariate analysis
delta (95 % C.I.) p delta (95 % C.I.) p
Age a 0.24 (0.14─0.33) < 0.0001 0.25 (0.18─0.32) < 0.0001
Sex (female) −0.29 (-0.99─0.40) NS
Disease (COPD vs asthma) 1.12 (0.42─1.81) <0.005
Previous experience with DPI 0.26 (-0.47─0.99) NS
Previous instructed to DPI 0.17 (-0.55─0.88) NS
Device (Breezhaler vs Genuair) 7.76 (7.15─8.37) < 0.0001 7.74 (7.15─8.33) < 0.0001
Device (Handihaler vs Genuair) 2.45 (1.78─3.12) < 0.0001 2.30 (1.65─2.95) < 0.0001
DPI dry powder inhaler, NS not significant
aEvery 5-years increment
bincluding patient time and nurse demonstration
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are only delivered through a fixed branded device, which
cannot be changed at pleasure, and the possible combi-
nation of a particular molecule with a particular device is
not possible in the great majority of cases yet.
The interest in patient’s preference revamped in recent
years [21, 23–27] due to the increased awareness that
PUP would contribute to a better adherence to the thera-
peutic strategy, thus leading to increased effectiveness of
treatment.
Just stemming from this evidence, the devices’ usability
and the understanding of procedures for their proper
actuation are of great value because they can greatly con-
tribute to differentiate the performances of different DPIs.
The possibility of grading objectively the performance of
each device in terms of both usability and therapeutic
convenience in daily life would represent a strong oper-
ational index [22, 28], particularly when derived from spe-
cific, comprehensive, and validated investigational
instruments [14, 15, 21, 23].
Results of the present study point out to the real diffe-
rences assessed by the Handling Questionnaire among
the devices when compared in terms of patient’s prefer-
ence and usability. Genuair was the most preferred, and
the device which was characterized by the lowest degree
of difficulties in understanding the manoeuvres needed
for actuating the inhalation properly and effectively.
Moreover, Genuair also proved the easiest to use and the
least problematic according to both the patients’ and the
nurse’s judgement (0.0001), the most easily learned
(0.0001), and that one with a successful rate of more than
56 % at the first attempt. These data are confirming
results of some previous studies which documented
Genuair as the most preferred DPI when compared to
Breezhaler and Handihaler [25–27, 29].
In terms of preference, to note that sometimes there is a
substantial discrepancy between the patients’ belief “at
glance” and the patients’ effective usability with some
devices in real life. It is the particular case of Breezhaler
which confirms again the existence of conflicting data
when the patients’ opinion “at glance” is compared to the
objective opinion of the nurse who is carefully attending
all the steps of the patients’ procedures with each device
tested in the study. This particular issue is a true crucial
point because, if the effectiveness of inhalation treatments
is highly depending on the proper use of devices (such as,
of DPIs in the case), both the patients’ and the health care
professionals’ judgment of preference is frequently based
on simplistic criteria which are mainly founded on sub-
jective perceptions rather than on effective handling skills.
On the other hand, both the duration of the nurse’s
explanation and the number of actions required for the
actuation of devices proved statistically related to the
number of patients’ attempts for the first proper actuation
and also to the probability of a successful actuation at the
first patient’s attempt.
Data of the present investigation confirmed that the
patient’s criteria of preference and usability are not
influenced substantially by a previous generic experience
with DPIs. Actually, only the successful rate at the first
attempt seems significantly affected according to the
univariate and multivariate regressions, while the num-
ber of attempts for the first proper inhalation and the
total time required for the first proper inhalation re-
sulted not significantly changed. On the other hand, no
data were available concerning the duration and the
quality of the instruction previously received by patients
included in the study. This evidence tends to strongly
emphasize how volatile can be the effects of the
Fig. 4 Pairwise comparison between the three devices investigated: arrows’ direction represents which device is superior (with statistical
significance according to p); e.g. the black arrow joining Genuair and Breezhaler means that Genuair results statistically superior
(p < 0.05) to Breezhaler according to the number of attempts before achieving the first proper inhalation (such as, Genuair needs less attempts)
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educational approach to inhalation devices in real life
when not institutionally structured or carried out by
non-professionals figures. Obviously, the outcomes of
any inhalation treatment can be affected particularly in
those patients suffering from persistent airway flow limi-
tation who need long-term therapeutic strategies.
From a general point of view, devices requiring less man-
ual actions for their actuation confirmed their better usa-
bility and proper handling after less attempts. In particular,
Genuair came out as the most preferred DPI also when
several different domains of preference were investigated
and compared, such as from aesthetic attractiveness up to
the perception of inhalation and the mouthpiece comfort.
Subgroup analyses showed slight differences between
asthma and COPD patients which are likely due to the
fact that asthma subjects were significantly younger.
Actually, asthma group proved to have less difficulty in
learning how to use devices and they prove a higher
successful rate at the first attempt than COPD patients.
While COPD patients perceived the ease of use for B
and C device equally, asthma patients preferred device B
significantly.
The preference for Genuair when compared to other
DPIs was already assessed in generic terms for COPD
patients [23], but the patient’s point of view was never
compared with that of an expert nurse previously. Further-
more, in the present study the time spent for instruction
and the number of attempts for achieving the proper actu-
ation were investigated analytically by linear and logistic re-
gression in order to define the possible influence of the
patient’s preference and acceptability. The comparison of
Genuair vs Breezhaler and Handihaler was never carried
out previously at our knowledge, even if Breezhaler was
proved much less preferred than Genuair in a recent study
aimed to assess the patient’s satisfaction and the inhaler
technique errors in COPD with these two devices [29].
Conclusions
DPIs, even though belonging to the same family of inha-
lation devices, are characterized by several technological
differences which make each device different from the
others of the family. Their gripping, size, manoeuvres for
actuation, understanding of inhalation procedures repre-
sent some relevant characteristics which can change sub-
stantially from each other, and then the patients’
acceptability and usability can change accordingly.
Only objective and measurable indicators should be
used for assessing and comparing the real-life perfor-
mances of DPIs in terms of patients’ preference and
usability. In order to provide a comprehensive assessment
of each device performance, the number of patients’
attempts for the first proper actuation, together with the
successful rate at the first attempt, and the total time
required for the first proper actuation represent the three
main determinants of usability which should greatly
contribute to the objective judgment of any DPI conveni-
ence in real life.
When compared to Breezhaler and Handihaler in terms
of these aspects, Genuair proved the DPI characterized by
the highest level of preference, usability, and convenience
in real life by patients with persistent airflow limitation.
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